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Latent membrane protein 2B regulates susceptibility to induction
of lytic Epstein-Barr virus infection
Abstract
The B-lymphotropic Epstein-Barr virus (EBV) encodes two isoforms of latent membrane protein 2
(LMP2), LMP2A and LMP2B, which are expressed during latency in B cells. The function of LMP2B is
largely unknown, whereas LMP2A blocks B-cell receptor (BCR) signaling transduction and induction
of lytic EBV infection, thereby promoting B-cell survival. Transfection experiments on LMP2B in
EBV-negative B cells and the silencing of LMP2B in EBV-harboring Burkitt's lymphoma-derived
Akata cells suggest that LMP2B interferes with the function of LMP2A, but the role of LMP2B in the
presence of functional EBV has not been established. Here, LMP2B, LMP2A, or both were
overexpressed in EBV-harboring Akata cells to study the function of LMP2B. The overexpression of
LMP2B increased the magnitude of EBV switching from its latent to its lytic form upon BCR
cross-linking, as indicated by a more-enhanced upregulation and expression of EBV lytic genes and
significantly increased production of transforming EBV compared to Akata vector control cells or
LMP2A-overexpressing cells. Moreover, LMP2B lowered the degree of BCR cross-linking required to
induce lytic EBV infection. Finally, LMP2B colocalized with LMP2A as demonstrated by
immunoprecipitation and immunofluorescence and restored calcium mobilization upon BCR
cross-linking, a signaling process inhibited by LMP2A. Thus, our findings suggest that LMP2B
negatively regulates the function of LMP2A in preventing the switch from latent to lytic EBV
replication.
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The B-lymphotropic Epstein-Barr virus (EBV) encodes two isoforms of latent membrane protein 2 (LMP2),
LMP2A and LMP2B, which are expressed during latency in B cells. The function of LMP2B is largely unknown,
whereas LMP2A blocks B-cell receptor (BCR) signaling transduction and induction of lytic EBV infection,
thereby promoting B-cell survival. Transfection experiments on LMP2B in EBV-negative B cells and the
silencing of LMP2B in EBV-harboring Burkitt’s lymphoma-derived Akata cells suggest that LMP2B interferes
with the function of LMP2A, but the role of LMP2B in the presence of functional EBV has not been established.
Here, LMP2B, LMP2A, or both were overexpressed in EBV-harboring Akata cells to study the function of
LMP2B. The overexpression of LMP2B increased the magnitude of EBV switching from its latent to its lytic
form upon BCR cross-linking, as indicated by a more-enhanced upregulation and expression of EBV lytic genes
and significantly increased production of transforming EBV compared to Akata vector control cells or LMP2A-
overexpressing cells. Moreover, LMP2B lowered the degree of BCR cross-linking required to induce lytic EBV
infection. Finally, LMP2B colocalized with LMP2A as demonstrated by immunoprecipitation and immuno-
fluorescence and restored calcium mobilization upon BCR cross-linking, a signaling process inhibited by
LMP2A. Thus, our findings suggest that LMP2B negatively regulates the function of LMP2A in preventing the
switch from latent to lytic EBV replication.
Epstein-Barr virus (EBV) is a ubiquitous B-lymphotropic
gammaherpesvirus which persists after primary infection la-
tently in the host for life and may switch periodically to its lytic
form (28). In vitro, EBV undergoes very efficient growth trans-
formation and immortalizes infected B cells by latent infection,
resulting in lymphoblastoid cell lines (LCLs) expressing a lim-
ited number of viral genes, including six viral nuclear antigens
(EBNAs) and latent membrane protein 1 (LMP1) and LMP2
(30). The ability to transform B cells implicates EBV as the
culprit for a variety of malignancies, including Burkitt’s lym-
phoma, Hodgkin’s disease, and posttransplant lymphoprolif-
erative disease (8, 24, 38). In vivo, EBV persists in latently
infected memory B cells circulating in the peripheral blood
(30). These latently infected cells do not express EBNAs or
LMP1, but may express LMP2 (1, 2). Since LMP2 has no
transformation capacity (12), this may suggest a pivotal role of
LMP2 in the regulation of the balance between latent and lytic
EBV.
Transcription of LMP2 is controlled by two promoters sep-
arated in the viral DNA by 3 kb (31). Two mRNAs that have
different 5 exons followed by eight common exons encode two
distinct proteins, LMP2A and LMP2B, respectively. LMP2A
contains an N-terminal cytoplasmic domain of 119 amino acids
with eight tyrosines that are phosphorylated in LCLs, 12 trans-
membrane domains, and a C-terminal domain of 12 amino
acids. LMP2A blocks B-cell receptor (BCR) signal transduc-
tion through specific phosphotyrosine motifs in its N-terminal
domain and promotes B-cell survival. This function is depen-
dent on the expression level of LMP2A (1, 2, 5, 6, 15, 21, 35).
LMP2B lacks the entire N-terminal cytoplasmic domain. A
recent work using transfection of LMP2 into EBV-negative
cells has suggested possible roles for LMP2B. LMP2B colocal-
ized with LMP2A in the membrane where the C terminus of
both splice variants can interact and regulate the activity of
each other (17). Furthermore, LMP2B was shown to negatively
regulate LMP2A activity by interfering with its aggregation
(29). Another study revealed protein domains of LMP2B
which are required for intra- and extracellular localization and
self-aggregation (37), which raised the question of whether the
function of LMP2B in EBV is bound to its localization inde-
pendently of LMP2A. Nevertheless, whether and how LMP2B
is involved in the regulation of latent and lytic EBV infection
in B cells harboring the functional virus remains a largely
unresolved question.
Burkitt’s lymphoma-derived Akata cells provide an optimal
model to study the balance between latent and lytic EBV.
Specifically, lytic EBV infection can be initiated in Akata cells
by cross-linking their BCR using anti-immunoglobulin G (anti-
IgG) (36). Importantly, upon induction of lytic EBV infection,
the majority of viral genes are expressed (3, 39). Since these
EBV genes could have an impact on the function of LMP2B,
we used Akata cells to investigate the function of LMP2B in
cells harboring functional EBV. Recently, we found that the
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silencing of LMP2B reduces susceptibility to induction of lytic
EBV infection upon BCR cross-linking (27). This result indi-
cated a role of LMP2B distinct from that of LMP2A in the
regulation of EBV lytic activation. In this work, we further
pursue the hypothesis that LMP2B exhibits a negative-regula-
tory effect on LMP2A maintenance of EBV latency. Thus, we
compared the effects of overexpression of LMP2B and LMP2A
on the susceptibility to induction of lytic EBV infection and on
cellular signaling pathways in Akata cells.
MATERIALS AND METHODS
Cell lines and primary cells. The Burkitt’s lymphoma cell line Akata (36) was
grown in RPMI 1640 supplemented with 10% fetal calf serum, L-glutamine (2
mM), penicillin (100 U/ml), and streptomycin (100 g/ml). Akata cells were a
kind gift of A. Bell (Birmingham, United Kingdom). Akata cells transfected with
the plasmids pEneo (33), pEneo-LMP2A (27), and pEneo-FLAG-LMP2B,
named Akata-vector (27), Akata-LMP2A (27), and Akata-LMP2B pools 1 to 3,
respectively, were cultured in the same medium supplemented with 0.4 mg/ml
G418 (Promega, Mannheim, Germany). Akata-cre cells that stably overexpress
the regulatable creERT2 recombinase (9) integrated into the vector pcDNA3.1
were cultured in the same medium supplemented with 0.4 mg/ml G418 (Pro-
mega, Mannheim, Germany). Cord blood mononuclear cells (CBMC) were
obtained from heparinized blood by Ficoll-Hypaque gradient centrifugation
(Amersham Biosciences Europe GmbH, Otelfingen, Switzerland) and washed
with phosphate-buffered saline (Gibco, Invitrogen Life Sciences, Basel, Switzer-
land). Informed consent was obtained from parturient women. The Zurich in-
stitutional ethics committee approved the collection and use of clinical material.
B95.8 cells were cultured in Dulbecco’s minimal essential medium supplemented
with 10% fetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml), and
streptomycin (100 g/ml) (23).
Plasmids. The sequence coding for LMP2B was PCR amplified from the
vector pSG5-LMP2 (15, 31) with following primers, including cloning adapters
and 3 FLAG for LMP2B tagging: FLAG-LMP2B-F (5-CGCGTTTAAACAT
GGACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGAT
TACAAGGATGACGATGACAAGAATCCAGTATGCCTGCCTG-3) and
LMP2-Rev (5-GCGCTCGAGTTATACAGTGTTGCGATATGGGGTC-3).
The PCR product was cloned via PmeI/XhoI into the Moloney murine leukemia
virus-derived pEneo bicistronic expression vector containing an internal ribo-
some entry site with a neomycin selection marker (33), resulting in the vectors
pEneo-FLAG-LMP2B and pEneo-LMP2A (27). Positive clones were verified by
sequencing. The parental pEneo plasmid was used as the control vector.
Transfection. Cells (1  106) were electroporated with 2 g of the pEneo,
pEneo-LMP2A, or pEneo-FLAG-LMP2B plasmid with Nucleofector II (Amaxa
GmbH, Cologne, Germany) with Buffer T and the program A-23. Electroporated
cells were allowed to recover for 2 days and were then selected with 0.8 mg/ml
G418 (Promega) for 2 to 3 weeks until resistant cells arose. These cells were
named Akata-vector, Akata-LMP2A, and Akata-LMP2B pools 1 to 3, respec-
tively. One month after selection, cells were supplemented with 0.4 mg/ml G418
and used for experiments. To generate double-transfected Akata cells, either
stable Akata-LMP2B cells were electroporated transiently (t) with the vector
pEneo-LMP2A (named 2B  At) or Akata-LMP2A cells were electroporated
transiently with the vector pEneo-FLAG-LMP2B (named 2A  Bt).
Immunoblot analysis. Total cellular protein extracts were prepared by disrup-
tion of cells in radioimmunoprecipitation assay lysis buffer (150 mM NaCl, 1%
NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], and 50 mM Tris,
pH 7.5). After denaturation for 10 min in 4 loading LDS buffer (Invitrogen,
Basel, Switzerland), samples were separated on a 10% Bis-Tris gel (Invitrogen)
and transferred to a nitrocellulose membrane (Schweitzer & Schell Bioscience
GmbH, Dassel, Germany). Membranes were blocked with 5% low-fat milk in 1
phosphate-buffered saline (PBS)–0.1% Tween 20 and incubated with either
mouse anti-FLAG M2 (Sigma, St. Louis, MO), rat anti-LMP2A (clone 14B7) (5),
or anti-c-myc (A-14; Santa Cruz Biotech, Inc., Santa Cruz, CA) antibody over-
night at 4°C. Immunoreactive proteins were detected by the secondary antibodies
against mouse and rabbit, respectively (Cell Signaling Technology, Danvers,
MA) and an enhanced chemiluminescence detection kit (SuperSignal West
Femto; Perbio Science Switzerland S.A., Lausanne, Switzerland).
IP. Total cellular protein extracts were prepared by disruption of 5  106 cells
in Tris nondenaturing lysis buffer (150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, and 50 mM Tris, pH 7.5), 2 mM NaF, and 2 mM Orthovanadate (all from
Sigma). Isolated proteins were immunoprecipitated with a Sigma immunopre-
cipitation (IP) kit according to the manufacturer’s instructions. IPs were per-
formed with the same antibodies used for immunoblotting or without an anti-
body.
Immunostaining. Cells (5  104) were centrifuged by Cytospin on double
Cytofunnel glass slides (Thermo, Waltham, MA) and fixed with methanol for 10
min at 20°C. Cells were permeabilized with 1% Triton X-100 in 1 PBS for 20
min at room temperature. Immunoreactive proteins were detected with a rat
anti-LMP2A antibody, 14B7 (1:100), and a secondary Alexa 488-labeled goat
anti-rat IgG antibody diluted 1:200 (Molecular Probes, Invitrogen). FLAG-
tagged LMP2B was detected with anti-FLAG M2 from Sigma (1:500) and a
secondary Alexa 594-labeled goat anti-mouse IgG antibody diluted 1:200 (Mo-
lecular Probes, Invitrogen). BZLF1 was detected with anti-BZLF1 (Argene,
North Massapequa, NY) diluted 1:100 and probed with the same secondary
antibody used for FLAG detection.
Flow cytometry. To evaluate the surface IgG (sIgG) content of transfected
cells for later stimulation experiments with BCR cross-linking, cells were fixed in
4% paraformaldehyde (Sigma) and stained with a phycoerythrin-labeled anti-
human IgG1, antibody (BD Biosciences, Basel, Switzerland). A phycoerythrin-
labeled anti-mouse IgG1, antibody (BD Biosciences) was used as an isotype
control. To determine the percentage of cells in which EBV was activated by
BCR cross-linking, 0.5 106 cross-linked and non-cross-linked cells were stained
with a fluorescein isothiocyanate (FITC)-labeled antiviral gp350/220 antibody
diluted 1:10 (Biodesign International, Saco, ME) and analyzed by flow cytometry
(FC-500; Beckmann-Coulter, Krefeld, Germany).
BCR cross-linking of Akata cells. Akata cells were split to 0.5  106 cells/ml
24 h before BCR cross-linking. Cells (0.5  106/ml) were then BCR cross-linked
with 0.1 g/l polyclonal rabbit anti-human-IgG (Dako, Zug, Switzerland) for
3 h and suspended afterwards in fresh RPMI 1640. Cross-linked and non-cross-
linked cells were collected for subsequent analyses.
qRT-PCR. Total RNA was extracted from 0.5  106 cells with an RNeasy kit
from Qiagen (Hombrechtikon, Switzerland). DNase [DNA-free; Ambion (Eu-
rope), Huntington, Cambridgeshire, United Kingdom] treatment was performed
before cDNA synthesis with an Omniscript RT kit (Qiagen). Quantitative real-
time PCR (qRT-PCR) was done with validated TaqMan systems for the house-
keeping gene HMBS and the lytic EBV genes BZLF1, BXLF1, and LMP2 (14) on
an ABI 7200 (Applied Biosystems). TaqMan data were analyzed using SDS 2.2
(Applied Biosystems), and mRNA expression was normalized to HMBS mRNA,
resulting in threshold cycle (CT) values. CT values were further normalized by
dividing “cross-linked” by “not cross-linked” values, resulting in CT values.
qRT-PCR data for control vector CT were set to 100% and LMP2B- or
LMP2A-overexpressing cells were compared to it.
Transformation assay. Fifty thousand freshly isolated CBMC per well were
seeded in a 96-well plate. Culture supernatants were filtered through a 0.45-m
polyvinylidene difluoride Millex-HV filter (Millipore Corporation, MA). Fifty
microliters of filtered culture supernatant of cells 24 h after anti-IgG cross-
linking or no cross-linking was added to a final volume of 100 l per well. A total
of 10 wells for each filtered culture supernatant was plated and inoculated.
Filtered supernatant from B95.8 served as the positive control, whereas the
negative control was CBMC cultured with medium only (23). The transformation
capacity was monitored by counting the wells after 6 weeks, when growth and
clustering of cells could be observed (34). The percentage of transformation was
calculated by setting 10 transformed wells to 100% and by normalization to the
transformation capacity of the supernatant of cells that were not cross-linked,
representing the spontaneous activation of EBV in Akata cells. Statistics were
done with Prism 4 (GraphPad Software, Inc.).
Calcium mobilization. Cells (5  106) were stained with Fluo-3 (6 M final
concentration) and Fura-Red (15 M final concentration; both from Invitrogen)
for 45 min in RPMI 1640 at 37°C. After a washing step with 1 PBS, cells were
stored at room temperature in the dark. Before measurement, cells were incu-
bated for 5 min at 37°C. Calcium mobilization was measured by adding ionomy-
cin (2 g/ml final concentration; Invitrogen) as the control and anti-IgG at the
same concentration as in stimulation experiments (100 g/ml) by using a FC-500
(Beckmann-Coulter) with an argon laser at 488 nm. Fluorescent emission was
recorded at 520 nm (Fluo-3) and 670 nm (Fura-Red), and the Fluo-3/Fura-Red
ratio was plotted against time. The baseline was recorded prior to anti-IgG
addition for 30 s and for 5 min after BCR cross-linking. The increase over the
baseline level was calculated for the time of peak of calcium mobilization (tp) by
using FlowJo 5.7.2 software. The percentage of responding cells was calculated
for the time slice from tp to tp  2 min. As an additional control, Akata-cre cells
were stimulated and the calcium mobilization was measured.
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RESULTS
Construction of LMP2B-overexpressing Akata cells. In or-
der to investigate the effects of LMP2B on LMP2A and the
switch from latent to lytic EBV replication, we first constructed
EBV-harboring Akata cells overexpressing either LMP2B or
LMP2A (27) and Akata cells with the vector control (27).
Given that no specific antibody against LMP2B exists, we
chose to tag LMP2B with a 3 FLAG sequence at the N
terminus. The tag was placed at the N terminus, since it has
been suggested that clustering of LMP2A and LMP2B occurs
over the common C termini and that LMP2B influences the
activity of its LMP2A isoform only when they colocalize (18,
29). As the transfection efficiency of B cells is low with com-
mon protocols, we decided to establish Akata cell pools stably
overexpressing LMP2B, LMP2A, or a control vector. Thus,
Akata cells were transfected independently with pEneo-
FLAG-LMP2B, pEneo-LMP2A, or the control vector pEneo
alone, as described in Materials and Methods. After neomycin
selection, stable overexpression of LMP2B was verified for all
three independently transfected Akata cell pools at the RNA
level by qRT-PCR and at the protein level by immunoblotting
and immunostaining. The three LMP2B-overexpressing cell
pools (Akata-LMP2B pools 1, 2, and 3) showed different levels
of overexpression of LMP2B after transfection (Fig. 1A). The
mRNA expression levels correlated with protein levels,
whereby Akata-LMP2B pool 1 showed a medium level, pool
2 a high level, and pool 3 the lowest level of LMP2B mRNA
and protein, respectively (Fig. 1B). Immunostaining was done
with Akata-LMP2B pool 2. Most overexpressed LMP2B local-
ized to cytosolic compartments, whereas smaller amounts were
detected in the plasma membrane (Fig. 1C). Furthermore, all
cell lines were stained for sIgG and were found to express sIgG
in similar percentages (Table 1). Thus, similar prerequisites for
susceptibility to stimulation by BCR cross-linking with anti-
IgG were ensured in the distinct cell lines.
LMP2B overexpression increases the magnitude of EBV
lytic activation after BCR cross-linking. To assess the distinct
effects of LMP2B and LMP2A on lytic activation of EBV in
FIG. 1. Generation of LMP2B-overexpressing Akata cells. (A) Overexpression of LMP2B pools 1 to 3 (2B-1, 2B-2, 2B-3) by qRT-PCR using
specific TaqMan systems targeting HMBS and LMP2 mRNA, respectively. (B) Immunoblot of FLAG-LMP2B pools 1 to 3 (2B-1, 2B-2, 2B-3).
(C) Immunostaining of FLAG-LMP2B in Akata-vector control cells and Akata-LMP2B pool 2 (2B-2).
TABLE 1. Characteristics of Akata cells useda
Cell line Vector construct % sIgG cells
% Cells activated by gp350/220 staining
0 h
24 h
Cross-linked Not cross-linked
Akatab None 96  1 ND ND ND
Akata-vectorb pEneo 92  2 0.30  0.11 4.62  0.06 0.58  0.09
Akata-LMP2Bc pEneo-FLAG-LMP2B 88  4 0.36  0.20 5.42  0.94 0.69  0.23
Akata-LMP2Ab pEneo-LMP2A 92  1 0.24  0.05 1.00  0.81 0.34  0.13
a ND, not detected.
b Values are presented as means  SD from three independent experiments.
c Values are presented as means  SD from pools 1 to 3.
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Akata cells, we stimulated Akata-LMP2B cells or Akata-
LMP2A cells and the corresponding Akata-vector control cells
by BCR cross-linking. After 24 h, cross-linked and non-cross-
linked cells were collected and examined by qRT-PCR for
expression of the immediate-early lytic gene BZLF1 and the
early lytic gene BXLF1 encoding the viral thymidine kinase.
The data were normalized to HMBS mRNA expression and
are presented as ratios of cross-linked to non-cross-linked cells
(Fig. 2). Akata-LMP2B cells showed mRNA expression levels
of BZLF1 and BXLF1 that increased 4-fold and 55-fold, re-
spectively (Fig. 2A). By contrast and as expected, transcription
levels of lytic EBV genes were reduced in Akata-LMP2A cells,
where expression of BZLF1 and BXLF1 mRNAs was reduced
by 97% and 99%, respectively (Fig. 2B). To confirm these
results at the protein level, we stained cells before and 24 h
after BCR cross-linking with a FITC-labeled antiviral gp350/
220 antibody in three independent stimulations. Indeed, as
determined by flow cytometry, Akata-LMP2B cell pools ex-
pressed up to 5.4-fold- and 4.6-fold-higher gp350/220 levels
than Akata-LMP2A cells and Akata-vector control cells, re-
spectively (Fig. 2C; Table 1).
LMP2B-overexpressing Akata cells produce more infectious
EBV than control cells upon BCR cross-linking. To verify the
complete activation of the EBV lytic cycle following BCR
cross-linking, the production of infectious EBV was monitored
by the transformation of primary human B cells (34). Follow-
ing BCR cross-linking of Akata-LMP2B, Akata-LMP2A, and
Akata-vector control cells, supernatants were prepared from
three independent experiments and added to freshly isolated
CBMC to determine the transformation capacity of the infec-
tious EBV produced. After normalization to non-cross-linked
cells, the transformation capacities of supernatants from
Akata-vector control cells were 67%, but those from Akata-
LMP2B-cell pools were up to 100% (P 	 0.0356), in contrast
to the 0% transformation capacity of supernatants from Akata-
LMP2A cells (P 	 0.0089; Fig. 3).
Overexpression of LMP2B decreases the degree of BCR
stimulation required to induce lytic EBV infection, in contrast
to overexpression of LMP2A. LMP2A blocks BCR signaling,
thereby impeding EBV lytic activation (6). It is not clear how
the expression level of LMP2A influences the degree of BCR
cross-linking (BCR activation) required to induce lytic EBV
infection and how this is affected by LMP2B overexpression.
Therefore, we assessed the magnitude of EBV lytic activation
as a function of the anti-IgG dose to engage BCR by cross-
linking Akata-vector, Akata-LMP2B, or Akata-LMP2A cells
with increasing concentrations of anti-IgG. To quantify the
activation of EBV lytic infection, mRNA expression of BZLF1
FIG. 2. LMP2B overexpression increases the magnitude of EBV lytic activation after BCR cross-linking, whereas LMP2A overexpression
results decreased magnitude. qRT-PCR with specific systems for HMBS, BZLF1, and BXLF1 mRNA, respectively, for Akata-vector control,
Akata-LMP2B (A), and Akata-LMP2A (B) 24 h after BCR cross-linking. Means and standard deviations (SD) of qRT-PCR results are from three
independent stimulation experiments on one representative polyclonal population. (C) Flow cytometry for gp350/220-FITC-labeled unstimulated
(gray line) or stimulated (black line) cells 24 h after BCR cross-linking. One representative measurement is shown for Akata-vector control,
Akata-LMP2B, and Akata-LMP2A cells with gp350/220-FITC-positive cells gated and indicated as percentages. Means and SD for three
independent experiments are summarized in Table 1.
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at 24 h after BCR cross-linking was measured (Fig. 4). Cross-
linked Akata-vector control cells compared to non-cross-
linked control cells showed an almost 100-fold increase of
BZLF1 mRNA expression with the lowest anti-IgG concentra-
tion of 5 g/ml and around 100-fold-higher peak BZLF1
mRNA expression levels with anti-IgG concentrations of 25
g/ml or higher. Akata-LMP2B cells showed a similar but
greater increase in BZLF1 mRNA expression and around five-
fold-higher peak levels than Akata-vector cells with anti-IgG
concentrations of 25 g/ml or higher. By contrast, Akata-
LMP2A cells required anti-IgG concentrations of at least 25
g/ml to show an increase in BZLF1 mRNA expression and an
anti-IgG concentration of 625 g/ml to show maximal BZLF1
mRNA expression levels, which were around 10-fold lower
than peak expression levels in Akata-vector cells. Thus, cells
with higher expression levels of LMP2A required higher doses
of anti-IgG to induce an EBV lytic activation, which was still of
a considerably lower magnitude than that for Akata-vector
control cells. These results suggest that the expression level of
LMP2A has an impact on the amount of BCR cross-linking
required to induce lytic EBV infection and that higher expres-
sion levels of LMP2A can be overridden, though only partially,
with a higher degree of BCR cross-linking. On the other hand,
higher LMP2B expression levels seemed to lower the degree of
BCR cross-linking required to induce EBV lytic activation and
to increase the magnitude of inducible EBV lytic activation.
LMP2B physically interacts with LMP2A before and after
BCR cross-linking in Akata cells. To investigate whether over-
expressed LMP2B physically interacts with endogenous
LMP2A, we isolated whole-cell protein extracts from Akata-
LMP2B pool 2 (2B-2) and Akata-vector control cells with a
subsequent pull-down IP of LMP2A. Subsequently, we per-
formed immunoblotting against FLAG tags and LMP2A (Fig.
5A). Indeed, coimmunoprecipitated LMP2B was detected by
anti-FLAG in Akata-LMP2B cells but not in Akata-vector
control cells, whereas endogenous LMP2A was detected in
both. Control IPs, with an anti-c-myc antibody or without an-
tibody and subsequent immunoblotting against c-myc or FLAG
(Fig. 5B and C) showed no unspecific pull-down, confirming
the specificity of the IPs, despite the overexpression of FLAG-
LMP2B.
Next, to elucidate in which compartment LMP2B and
LMP2A localize, we transfected Akata-LMP2A (2A) tran-
siently with FLAG-LMP2B (Bt) (indicated as 2A  Bt) and
immunostained LMP2A or FLAG-LMP2B for fluorescent mi-
croscopy. The images shown in Fig. 6B suggest partial colocal-
ization of both LMP2 isoforms in the same cellular compart-
ments (Fig. 6B). Additionally, we found an accumulation of
LMP2B in the cytosolic region, as seen in stable Akata-LMP2B
and described above (Fig. 1C). To determine if there is a
relocalization of LMP2A or LMP2B upon BCR cross-linking,
we double-stained Akata-LMP2A cells transiently transfected
with FLAG-LMP2B (2A  Bt) for FLAG-LMP2B and for
LMP2A (Fig. 6C), and for BZLF1 and LMP2A (Fig. 6D) after
BCR cross-linking. An immunofluorescence analysis indicated
a rather modest shift of LMP2A and LMP2B into the cytosol
after BCR cross-linking, but still-adequate amounts of both
LMP2s were located in the same compartments as before BCR
cross-linking.
LMP2B restores calcium mobilization in LMP2A-overex-
pressing Akata cells. It has been previously established that
LMP2A blocks calcium mobilization induced by BCR cross-
linking (20–22). To investigate the impact of LMP2B overex-
pression on calcium mobilization, we determined the calcium
levels before (baseline) and after BCR cross-linking, monitor-
ing the kinetics for 5 min in Akata-vector control, Akata-
LMP2B pool 2 (2B-2), and Akata-LMP2A (2A) cells, respec-
tively. Additionally, Akata-cre cells overexpressing creERT2
FIG. 3. More infectious EBV is produced in LMP2B-overexpress-
ing Akata cells than in the control. Isolated CBMC were infected with
supernatant from Akata-vector control, Akata-LMP2A, or Akata-
LMP2B pools 1 to 3 collected 24 h after stimulation by BCR cross-
linking. The transformation capacity was monitored by counting the
wells after 6 weeks, at which time growth and clustering of cells indi-
cated transformation. The percentage of transformation was calcu-
lated by setting 10 wells showing signs of transformation to 100% and
by normalization to the transformation capacity of the supernatant of
the corresponding BCR non-cross-linked control cells, representing
the spontaneous EBV lytic activation in Akata cells. Means and SD are
from three independent stimulation experiments with subsequent col-
lection of supernatant and infection of CBMC. t tests were performed
with a 95% confidence interval. *, no wells showed signs of transfor-
mation.
FIG. 4. Overexpression of LMP2B decreases the degree of BCR
stimulation required to induce lytic EBV infection, in contrast to
overexpression of LMP2A. BZLF1 mRNA expression in Akata-vector
control (f), Akata-LMP2A (F), or Akata-LMP2B (Œ) 24 h after BCR
cross-linking using increasing doses of anti-IgG. Means and SD are
from three independent stimulation experiments on one representative
polyclonal population.
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recombinase in the cytosol were stimulated and monitored in
parallel to exclude any epiphenomena due merely to overex-
pression which could influence calcium mobilization. Calcium
mobilization reached up to 3-fold, 3.3-fold, and 3.5-fold peaks
compared to baseline levels after BCR cross-linking in Akata-
vector control cells, Akata-cre cells, and Akata-LMP2B cells,
respectively (Fig. 7). Next, we generated double transfectants
by electroporation of Akata-LMP2B cells transiently with the
vector pEneo-LMP2A (2B  At) as described in Materials and
Methods and measured the calcium mobilization after BCR
cross-linking. We observed not only a decrease of calcium
mobilization from 3.5-fold to 1.9-fold in Akata-LMP2B cells
but also a decrease of responding cells from 90% to 74%.
These results are in agreement with previous studies (20–22).
The calcium mobilization in Akata-LMP2A cells revealed the
same low calcium mobilization and percentage of responding
cells as observed in the double-transfected 2B  At cells (1.8-
fold and 77%, respectively). To address the question of
whether it is possible to rescue the phenotype of Akata-vector
control cells, we transiently transfected Akata-LMP2A cells
with the vector pEneo-FLAG-LMP2B (2A  Bt). Interest-
ingly, the calcium mobilization was restored to Akata-vector
control cell levels from 1.8- to 2.9-fold after BCR cross-linking.
Additionally, responding cells increased from 77% to 82% in
double-transfected 2A  Bt cells (Fig. 7).
DISCUSSION
In this work, we investigated the impact of LMP2B on the
potential of LMP2A to maintain EBV in its latent state. We
demonstrate that LMP2B increases the magnitude of EBV
switching from its latent to its lytic form upon BCR cross-
linking, lowers the degree of BCR cross-linking required to
provoke this switching, and is involved in augmenting signaling
via calcium mobilization upon BCR cross-linking in Akata cells
harboring functional EBV. These observations suggest a neg-
ative regulatory effect of LMP2B on the ability of LMP2A to
block BCR signaling, thereby preventing EBV from switching
from latent to lytic infection in B cells.
Although LMP2A and LMP2B are similar in their structure,
the lack of the signaling amino-terminal domain in LMP2B
indicates distinct functions for these two proteins. Indeed, the
overexpression of LMP2B in Akata cells resulted in higher
mRNA expression of immediate-early and early lytic EBV
genes upon BCR cross-linking, whereas the overexpression of
LMP2A results in lower mRNA expression in these genes.
FIG. 5. LMP2B coimmunoprecipitates with LMP2A. Whole-cell protein lysates of Akata-LMP2B pool 2 (2B-2) and the Akata-vector control
were immunoprecipitated (IP) with anti-LMP2A (A). The IPs were separated on a SDS gel and immunoblotted (IB) against FLAG and LMP2A.
The heavy band in the LMP2A immunoblot represents the heavy Ig chain of the mouse antibody used for pull-down, whereas the lower, narrow
band represents the equal amount of LMP2A pulled down in 2B-2 and vector input lysates. (B) The input lysate of 2B-2 was split into IPs without
antibody, against c-myc, and FLAG and immunoblotted (three dilutions; 1, 0.2, 0.04) against FLAG. No unspecific pull-down with anti-c-myc
was observed due to the overexpression of FLAG-LMP2B. (C) The same IPs as those used in panel B were loaded on a SDS gel and
immunoblotted against c-myc to verify that the IP was working. The upper band (65 kDa) and the lower band (63 kDa) in the input lysate of 2B-2
represent two forms of c-myc.
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Moreover, LMP2B overexpression leads as well to production
of more EBV envelope protein gp350/220 and functional virus
than do LMP2A-overexpressing or control Akata cells upon
BCR cross-linking. These findings are compatible with our
previous observation that silencing of LMP2B in Akata cells
reduces the susceptibility of these cells to undergo EBV lytic
activation induced by BCR cross-linking (27). Thus, our cur-
rent and previous data provide evidence that LMP2B is in-
volved in the regulation of EBV switching from latent to lytic
infection EBV in B cells harboring the whole virus in its latent
form.
The overexpression of LMP2B did not result in spontaneous
switching of latent to lytic EBV. Nevertheless, the higher mag-
nitude of EBV lytic activation in LMP2B-overexpressing Akata
cells than that in control Akata cells upon BCR cross-linking
with similar doses of anti-IgG suggested that LMP2B exerts its
mode of action through lowering the required degree of BCR
cross-linking and thus BCR signaling needed. Since LMP2A
blocks BCR signaling (5, 6, 12, 15, 21, 29, 30, 35), we addressed
the fundamental question of whether the magnitude of EBV
lytic activation at given expression levels of the LMP2s de-
pends on the dose of anti-IgG required to cross-link BCR, i.e.,
the degree of BCR cross-linking. Indeed, although increasing
doses of anti-IgG elevated the levels of activation of lytic EBV
in LMP2A-overexpressing Akata cells until they reached a
plateau, peak levels of induced lytic EBV in these cells were
around at least 10-fold lower than in control Akata cells or
around 30- to 50-fold lower than in LMP2B-overexpressing
Akata cells. This result suggests that both endogenous and
overexpressed LMP2A is able to reduce BCR signaling very
effectively and cannot be completely counteracted, even by
saturated levels of anti-IgG added for cross-linking. Thus, the
amount of overexpressed LMP2B was able to decrease the
activity of endogenous LMP2A on BCR signaling but could
not abolish it completely in whole-EBV-containing cells.
An important question to be addressed was if there is an
interaction of LMP2A and LMP2B in Akata cells harboring
EBV and, if so, where the two isoforms of LMP2 colocalize.
The physical interaction between LMP2A and LMP2B was
verified by pulling down FLAG-LMP2B with endogenous
LMP2A. Our immunostaining results suggest an accumulation
of LMP2B in intracellular compartments and to a lesser extent
on the plasma membranes of Akata cells harboring whole
EBV. Lynch et al. (17) reported that transiently expressed
LMP2B localized to perinuclear regions and colocalized with
transiently or constitutively expressed LMP2A in EBV-nega-
tive BJAB cells or LCL B95-8CR, respectively. Studies using
HEK 293 cells overexpressing full-length or deletion mutants
of LMP2A revealed a clustering signal of LMP2A at the C
terminus leading to homodimerization (18). As LMP2A and
LMP2B share eight exons and the C terminus, Rovedo and
Longnecker (29) hypothesized that LMP2B colocalizes with
LMP2A, forming heterodimers, and subsequently negatively
regulates LMP2A activity, leading to decreased degradation of
FIG. 6. Overexpressed LMP2B and LMP2A colocalize before and after BCR cross-linking. (A) Negative control for secondary antibodies.
(B) To investigate where LMP2B and LMP2A localize, we transiently transfected Akata-LMP2A cells with FLAG-LMP2B (2A  Bt) and stained
for LMP2A and FLAG-LMP2B. To determine if there occurs a relocalization of LMP2A or LMP2B upon BCR cross-linking, we stained the
double-transfected Akata cells (2A  Bt) for FLAG-LMP2B and for LMP2A (C) and for BZLF1 and LMP2A (D) 3 h after BCR cross-linking
(E). DAPI, 4,6-diamidino-2-phenylindole.
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the tyrosine kinase Lyn. A more-recent study showed that
when tagged LMP2B was overexpressed in BJAB cells or HEK
293T cells, LMP2B was found exclusively in intracellular peri-
nuclear compartments (29, 37), a result which is in apparent
contrast with the results of the aforementioned study. When
LMP2B was truncated at any domain, it resulted in localization
to the cell surface. Based on these results taken together, one
can hypothesize that the major impact of LMP2B on LMP2A
takes place in endosomes, where it interferes either with the
activity of LMP2A and subsequent ubiquitination and degra-
dation of Lyn or with the trafficking of LMP2A back to the
plasma membrane.
An immunofluorescence analysis of LMP2A and LMP2B
suggested a colocalization of LMP2A and LMP2B in Akata
cells overexpressing both proteins. We detected a rather mod-
est shift of LMP2B and LMP2A into the cytosol, which sug-
gests their internalization after BCR cross-linking. Neverthe-
less, a large amount of both LMP2s remains detectable on the
plasma membrane, demonstrating an intact turnover process.
Moreover, this experiment allowed us to exclude the possibility
of misfolded and degraded protein in the endoplasmic reticu-
lum due to overexpression, as has been reported in earlier
studies (10, 19). It is known that LMP2A aggregates in lipid
rafts, assembling as a signalosome which enables a transient
interaction with the tyrosine kinases Syk and Lyn with a sub-
sequent block of the BCR signal (5–7, 15, 16, 21, 25, 26, 35).
One can hypothesize that after BCR cross-linking, the anti-
IgG/BCR complex is internalized together with closely located
lipid rafts and LMP2A signalosomes. If there is an additional
function of LMP2A in preventing the whole complex from
being transported again to the cell membrane, in this way
blocking continuous stimulation, one can hypothesize that
there is a loss of LMP2A at the cell surface and an accumu-
lation in endosomes located in the cytosol after BCR cross-
linking. LMP2B, which is found in cytosolic compartments,
may intervene in this step, disrupting homodimerized LMP2A
and restoring the turnover.
As demonstrated here for the first time, calcium mobiliza-
tion upon BCR cross-linking is dependent on the expression
level of LMP2B in EBV-harboring Akata cells. As expected
from previous reports (20–22), we observed virtually no cal-
cium mobilization in LMP2A-overexpressing cells upon BCR
cross-linking. By contrast, after transient transfection of
LMP2B into LMP2A-overexpressing Akata cells, calcium mo-
bilization after BCR cross-linking is increased to levels com-
parable to those observed for Akata cells overexpressing
LMP2B. Conversely, we measured a reduced calcium mobili-
zation in LMP2B-overexpressing Akata cells transiently trans-
fected with LMP2A. As transiently transfected vectors express-
ing the gene of interest lead to high levels of protein, the
dominant effect on the stably transfected Akata cells was pre-
dictable. Three different signaling pathways which are acti-
vated upon BCR cross-linking in Akata cells have been ana-
lyzed: (i) calcium mobilization through phosphatidylinositol
3-kinase, (ii) c-Jun N-terminal kinase activation through Syk
and Lyn signaling, and (iii) ERK1/2 phosphorylation through
the RAS protein (4). Nevertheless, whether LMP2B is involved
partially or throughout all these signaling cascades, taking a
key regulatory function upstream, remains unknown. Rovedo
and Longnecker showed recently that in the EBV-negative
B-cell line BJAB, ectopically expressed LMP2B decreases the
activity of LMP2A by alteration of the phosphorylation status
(29). Thus, LMP2B would function at an initial step of BCR
signaling to restore BCR signal transduction which was
blocked by LMP2A. As a more downstream read-out, they
chose to measure the calcium mobilization in BJAB cells upon
BCR cross-linking. As has previously been shown, the overex-
pression of LMP2A nearly abolished calcium mobilization (20–
22). According to the hypothesis of BCR signal restoration by
LMP2B, ectopic overexpression of both splice variants of
LMP2 together resulted in the phenotype of BJAB transfected
with vector control only.
LMP2B may have important functions not only in the mod-
ulation of latent and lytic EBV infection in tumor cells or
FIG. 7. LMP2B restores calcium mobilization in LMP2A-overex-
pressing Akata cells. Calcium levels were determined before and after
BCR cross-linking, and the kinetics were measured for 5 min. Upper
panels, calcium mobilization after BCR cross-linking in Akata control
cells and, as an additional control, in Akata cells with epigenetic
overexpression of an unspecific protein in the cytosol (see Materials
and Methods). Middle panels, calcium mobilization after BCR cross-
linking in Akata-LMP2B cells without (2B) and with (2B  At) tran-
siently transfected LMP2A. Lower panels, calcium mobilization after
BCR cross-linking in Akata-LMP2A cells without (2A) and with (2A
Bt) transiently transfected FLAG-LMP2B. Baselines were measured
just before BCR cross-linking. The percentage of responding cells was
calculated as described in Materials and Methods.
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memory B cells in the periphery. As was reported previously,
LMP2A is expressed in newly infected naı¨ve B cells before
latency is established and serves as a tonic signal for survival.
This scenario might be true for B cells with crippled or a total
loss of BCR expression, leading in the worst case to Hodgkin’s
lymphoma (11, 13). In contrast, if a naı¨ve B cell which has a
functional BCR is newly infected and receives the survival
signal, the additional signal of LMP2A might resemble in total
an activated BCR, forcing EBV to lytic infection. In the pres-
ence of LMP2B, the signal of LMP2A would be downregu-
lated, not leading to activated lytic EBV as was suggested
previously for high levels of LMP2A (32).
In conclusion, the data presented here provide evidence that
LMP2B is involved in the regulation of switching from latent to
lytic EBV in B cells harboring functional EBV. Based on our
present and previous findings for Akata cells (27) together with
observations made for the EBV-negative cell line BJAB (29),
we suggest that LMP2B has an impact on the activity of
LMP2A, resulting in increased susceptibility to induction of
lytic EBV infection through modulation of BCR and down-
stream signaling.
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